The analysis of clinical indicators in patients with PCOS showed that BOP1 levels were substantially associated with the AFC, BMI, serum androgen level, and AMH level of the patients, which suggested that BOP1 could be a potential therapeutic target for PCOS. Here, AMH is linked to polycystic ovary syndrome.